bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

bioAffinity Technologies said sales of its CyPath Lung test increased more than 100% through the third quarter of 2026 compared with the same period in 2025, citing continued growth in clinical adoption. The announcement provides no absolute sales figures.

Analysis

The key question is whether reported sales growth reflects a meaningful increase in paid tests or a large percentage change from a small base. Neither the release excerpt nor the growth rate establishes revenue scale, repeat ordering, reimbursement, or attractive unit economics. The market may price adoption ahead of evidence that test use converts into durable gross profit and lower cash burn.

Over the next 1–3 months, the useful catalysts are disclosed absolute test volumes, realized revenue per test, payer coverage and collections, and updated cash usage—not another percentage-growth claim. Over 6–18 months, sustained clinician adoption and evidence that the test complements existing lung-screening pathways could support a broader commercial case; weak reimbursement or limited repeat use would reverse it. Established imaging and diagnostic pathways are the competitive constraint, while wider adoption could benefit screening providers only if testing expands rather than displaces existing care.

Contrarian read: the growth headline is positive but may be under-informative, not necessarily underappreciated. Treat BIAF as a proof-of-commercialization situation, not a validated earnings-growth story. No trade is warranted from this release alone; verify the growth denominator, absolute sales, and cash runway before taking directional exposure.

Key Decisions for Investors

• Do not chase BIAF solely on the reported growth rate. Reassess after the next filing or earnings update provides absolute test sales/volume and revenue contribution.
• Place BIAF on a catalyst watchlist: track payer coverage and collections, repeat ordering by providers, gross margin, and cash burn. These determine whether adoption can become self-funding.
• Falsification: treat the thesis as impaired if subsequent disclosures show slowing test volumes, weak realized revenue relative to test growth, reimbursement delays, or materially worsening cash usage.
• Avoid a forced peer pair trade: the release supplies no comparable unit economics or adoption data. Revisit only if commercial metrics permit a defensible comparison with established lung-screening and diagnostic pathways.